Compare AbCellera Biologics Inc (ABCL) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Vanguard Total World Stock Index Fund ETF trades at $155.5. Which is the better fit depends on your goals.
| ABCL | VT | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $8.12 | $159.35 |
52-Week Low | $2.78 | $128.41 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Vanguard Total World Stock ETF (VT) trades at $157.81, up 1.05% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings but faces overbought conditions on short-term RSI. Recent news highlights VT's global diversification advantages with over 10,000 holdings, though competitors offer lower expense ratios.
VT provides comprehensive global equity exposure but lacks available fundamental ratios in current data. The ETF's 1.6% dividend yield and broad diversification support long-term positioning, though expense ratio comparisons with peers like SCHF (0.03%) present competitive considerations for cost-conscious investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
